JPRN-UMIN000049997
Not yet recruiting
未知
An observational study to evaluate the safety and efficacy of lenvatinib plus pembrolizumab combination therapy for advanced or recurrent uterine cancer after use of platinum-based drugs(GOGO-EM4) - GOGO-EM4
Gynecologic Oncology Group of Osaka(GOGO)0 sites100 target enrollmentJanuary 10, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Gynecologic Oncology Group of Osaka(GOGO)
- Enrollment
- 100
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with recurrent endometrial cancer who have not received any chemotherapy, including platinum\-based antineoplastic agents 2\. Cases with obvious infection 3\. Cases with active multiple cancers 4\. Patients with persistent adverse events (Common Terminology Criteria for Adverse Events \[CTCAE] version 5\.0 Grade 2 or higher) from prior chemotherapy(Excluding epilation and peripheral neuropathy) 5\. Cases with hematologic complications 6\. Cases with a history of bone marrow transplantation 7\. Cases with uncontrolled brain metastases 8\. Patients with serious complications (cardiac disease, uncontrolled diabetes, malignant hypertension, bleeding tendency, etc.) 9\. Pregnant or lactating patients and patients of childbearing potential (will) (except for patients using appropriate contraceptive methods) 10\. Any other cases other than those listed above that the principal investigator deems inappropriate for enrollment of the case in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
An observational study to evaluate the safety and efficacy of MegaDerm Soft in patients who underwent breast reconstruction using the MegaDerm soft.KCT0007432Soon Chun Hyang University Hospital Bucheon60
Recruiting
Phase 4
An observational study to evaluate the safety and efficacy of FOLFIRI / FOLFOX plus Cetuximab as first-line therapy inpatients with KRAS wild-type metastatic Colorectal cancerHealth Condition 1: null- Patients with KRAS wild-type metastatic Colorectal cancerCTRI/2010/091/000161Merck Specialities Pvt Limited5th Floor , Shivsagar EstateDr. Annie Besant RoadMumbai 400018100
Recruiting
Phase 4
An Observational Study to evaluate the safety and efficacy of Cetuximab in combination with platinum-based chemotherapy, in the first-line therapy of recurrent/ metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CTRI/2010/091/000170Merck Specialities Pvt Ltd5th Floor Shiv Sagar Estate, Dr. Aniie Besant Road, WorliMumbai 400018100
Recruiting
Not Applicable
An observational study to investigate the safety and efficacy of niraparib for Japanese patients with recurrent ovarian cancer: maintenance therapy for platinum-sensitive recurrent treatment and monotherapy for late-line treatmentOvarian cancer, fallopian tube cancer, primary peritoneal cancerJPRN-UMIN000046970Japanese Gynecologic Oncology Group180
Completed
Not Applicable
An observational study to investigate the safety and efficacy of niraparib maintenance therapy after primary chemotherapy for Japanese patients with advanced ovarian, fallopian tube, or primary peritoneal cancerovarian cancer, fallopian tube cancer, primary peritoneal cancerJPRN-UMIN000045931Japanese Gynecologic Oncology Group300